In early trading on Monday, shares of clinical-stage drug developer Keros Therapeutics, Inc. (KROS) rose by 2.1%, following the announcement of its plan to repurchase up to $194.4 million of its own stock. This initiative is part of a broader capital return program totaling $375 million, reflecting Keros's commitment to enhancing shareholder value through its strategic growth initiatives.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments